Rana Mahmood, MD
Neurology · Decatur, ILNPI 1043363211
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by AbbVie at 35.6% of the total. Reporting peaked in 2021 at $9,220 and has fallen 83.6% since, to $1,510 in 2025. Among neurology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $63.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Biohaven Pharmaceuticals, Inc.$4K
- Livanova USA, Inc.$2K
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$580
- plus $4K from 43 others
What the payments were for
- Speaking & faculty fees$16,16259%
- Travel & lodging$2,92411%
- Food & beverage$7,36927%
- Education$7583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$9,098
- UBRELVY$8,175
- VNS Therapy$1,371
- Inspire$780
- VNS - Sentiva$475
- ULTOMIRIS$400
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$139
- QELBREE$107
How this compares
$27,213 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $244,202 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $186,362 |
| Sodium Oxybate | 13 | $150,088 |
| BotoxOnabotulinumtoxina | 49 | $122,199 |
| TecfideraDimethyl Fumarate | 11 | $102,229 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 14 | $82,229 |
| NuplazidPimavanserin Tartrate | 14 | $68,715 |
| Aimovig AutoinjectorErenumab-Aooe | 33 | $30,288 |
| BriviactBrivaracetam | 16 | $29,308 |
| Nurtec OdtRimegepant Sulfate | 15 | $17,409 |
| Emgality PenGalcanezumab-Gnlm | 24 | $16,735 |
| QuliptaAtogepant | 13 | $16,254 |
| Lacosamide | 170 | $14,387 |
| NeuproRotigotine | 17 | $13,934 |
| SunosiSolriamfetol Hcl | 16 | $13,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $15 | $186,36215 claims |
| AbbVieBotox, Qulipta | $9,689 | $138,45362 claims |
| BiogenTecfidera | $57 | $102,22911 claims |
| PfizerOctagam, Nurtec Odt | $61 | $99,63829 claims |
| Acadia Pharmaceuticals IncNuplazid | $73 | $68,71514 claims |
| UCB, Inc.Briviact, Neupro | $302 | $43,24133 claims |
| Axsome Therapeutics, Inc.Sunosi | $94 | $13,64716 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $16 | $12,47787 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $15 | $5,63911 claims |
| Upsher-smith Laboratories LLCTopiramate | $51 | $4,146262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.
Other neurology in Decatur
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.